WCLC: Merck analyses throw doubt on new biomarker's utility FiercePharma
Looking to find their niche in the ultra-lucrative non-small cell lung cancer market, some immuno-oncology companies have turned to investigational biomarker ...
(CLICK HERE TO READ AND SEE MORE)
0 comments:
Post a Comment